Source: https://www.bio.org/category/conferences-events/bio-ip-counsels-committee-conference
Timestamp: 2019-04-23 20:20:17+00:00

Document:
All sessions take place at the Conrad Indianapolis, in the Vienna Ballroom, South, unless otherwise noted.
Opening Session: Cousins Once Removed - What Can Medical Biotechnology Learn from Patent Litigation in Industrial and Agricultural Biotech?
This panel will discuss recent legal trends in patent litigation involving agricultural and medical biotechnologies. Using a cross-disciplinary perspective, panelists will review recent key cases, examine how the similarities and differences between industries shape litigation strategy, and offer practical advice.
Education Session 1: Obviousness-Type Double Patenting – Where Are We, and Is It Time for a Legislative Clarification?
Obviousness-type double patenting was created to fill a gap in the patent statute, but it has moved beyond that narrow purpose and has threatened otherwise valid and unobvious patents. This panel will discuss the recent case law of the Federal Circuit, strategies to take during prosecution to reduce risk, and legislative efforts to address this problem.
Walking group will depart from the Conrad Indianapolis main lobby at 5:25 pm.
From on-sale bar to sovereign immunity, this panel will discuss several recent important cases and their impact on the life sciences community. Specifically, we will review key Supreme Court and Federal Circuit cases addressing challenges associated with enforcement and damages, including: on-sale bar under AIA (Helsinn v. Teva), implications of sovereign immunity in IPR proceedings (U. Minnesota v. LSI), questions around standing to appeal a PTAB decision (Momenta v. BMS), the latest on induced infringement (GSK v. Teva), and the issues of lost foreign profits and apportionment for patent infringement (WesternGeco v. ION Geophysical Corp. and Power Integrations v. Fairchild Semiconductor).
This panel will discuss current IPR statistics with a focus on biologic and small molecule drug IPRs. This will include statistics on IPR institution rates overall, for biologics and small molecule drugs, and the impact of Patent Owners submitting declarations with their Preliminary responses. We will also take a look at whether institution rates are changing after the April Supreme Court decision in SAS Institute. Further discussion will include statistics relating to serial petitions and varying institution and final written decision outcomes based on claim types challenged.
Gonzalo Merino, PhD, Chief Intellectual Property Counsel, Regeneron Pharmaceuticals, Inc.
While CRISPR technology promises technological breakthroughs in genetic manipulation and the associated treatment of disease, it poses challenges to U.S. Patent law. The panel will discuss these challenges and potential ways to address them.
Join your colleagues for a brief happy hour networking session prior to our evening at the Indycar Factory!
Get your adrenaline pumping with a variety of interactive exhibits and activities centered around the world’s fastest sport. Take in the history and engineering involved in designing, building, and supporting some of the world’s most competitive race cars, and get in the racing spirit with full size Indycar race simulators and a real time pit stop challenge in the Interactive Hall before sitting down to dinner among Indy 500 race cars. Transportation will depart from the Illinois Street exit of the Conrad Indianapolis at 5:15 pm. Return shuttles will depart Dallara Indycar Factory at 8:00 pm and 8:30 pm.
This panel will discuss the new FDA Biosimilar Action Plan and stakeholders’ responses as well as recent FDA Guidances concerning biologics, biosimilars and interchangeables and their potential impact on IP from R&D and biologic developments into the future.
Claire Vasios, Vice President, Intellectual Property, Alkermes, Inc.
This panel will discuss recent happenings in trade secret law, including a national uptick in trade secret litigation, important US cases from the past year, and international perspectives on trade secret litigation.
BIO has reserved a block of hotel rooms for registered IP Counsels Committee Conference attendees at the conference hotel, the Le Meridien Denver Downtown, located in the heart of downtown Denver!
The group discount deadline - Monday, March 18 - has passed and the group rate is no longer available. Please check directly with the Le Meridien for current availibility and rates online.
BIO is offering a discount for first time in-house attendees. For a limited number of qualified applicants, BIO will waive the registration fee and reimburse up to $500 in hotel and airline expenses. Recipients must be employed at a R&D biotech company and have never attended a BIO IPCC Conference before.
Are you part of a small in-house IP group or have not had the opportunity to attend a biotech-focused IP conference? This would be a great opportunity to connect with similarly-situated in-house colleagues, get updates and analysis on patent law developments, share best practices, and participate in policy discussions that affect our industry. Please contact kreyes@bio.org if you believe you qualify for the discount.
You are now opted out of 2018 IPCC communications. Want to opt back in? Please click here to set your email preferences.

References: v. 
 v. 
 v. 
 v. 
 v. 
 v.